广州医科大学学报

目的:观察替普瑞酮治疗萎缩性胃炎的临床疗效。方法:205例慢性萎缩性胃炎(chronic atrophicgastritis,CAG)患者随机分为两组,治疗组(101例)连续口服替普瑞酮胶囊,对照组(104例)口服安慰剂,总疗程20周。观察两组治疗前后症状、胃镜检查及胃黏膜组织学检查改变。结果:治疗组临床症状改善有效率87.1%,对照组52.9%,两组比较差异有统计学意义(P<0.05);胃镜下黏膜改变:治疗组总有效率92.1%,对照组60.6%,两组比较差异有统计学意义(P<0.05)。胃黏膜组织学变化比较显示:治疗组总有效率为90.1%,对照组54.8%,两组比较差异有统计学意义(P<0.05)。结论:替普瑞酮是治疗慢性萎缩性胃炎安全有效的药物。

Objective:To investigate the efficacy of teprenone in the treatment of atrophic gastritis.Methods: 205 patients with atrophic gastritis were randomly divided into 2 groups,to receive a 20-week therapy with teprenone (teprenone treatment group,n = 101 ) or with placebo(control group,n = 104 ).Major symptoms,findings of gastroscopy and histology of gastric mucosa were recorded before and after the treatment,and compared between the two groups.Results:The rates of response in the teprenone treatment group was 87.1%vs 52.9%in the control group by symptom relief(P<0.05 ),92.1%vs 60.6%by gastroscopy(P<0.05 ),and 90.1%vs 54.8%by histology(P<0.05).Conclusion:Teprenone can safely and effectively protect against chronic atrophic gastritis.